Barbara L. McAneny, MD, To Serve as Chair of the AMA Board of Trustees
Barbara L. McAneny, MD, a practicing oncologist from Albuquerque, New Mexico, has been re-elected to the Board of Trustees of the American Medical Association (AMA) and will assume the position of Board Chair when the trustees gather for their first postelection meeting. Dr. McAneny, who has been a Board member since 2010, has been Chair-Elect of the Board for the past year. Her re-election to the AMA Board affirms her transition to Board Chair.
“I am honored to be re-elected to the American Medical Association Board of Trustees,” said Dr. McAneny. “I hope to help AMA to continue to lead the way in providing the support and structures needed to unleash the creativity of American physicians to provide the highest possible level of patient and physician satisfaction.”
Prior to her election to the AMA Board, Dr. McAneny served on the Board for the American Society of Clinical Oncology (ASCO) and was the delegate to the AMA from ASCO. She has held many leadership roles including President of the New Mexico Medical Society (NMMS), President of the Greater Albuquerque Medical Association, and President of the New Mexico Chapter of the American College of Physicians. She served as Chair of the AMA Council of Medical Service from 2009 to 2010.
Dr. McAneny is the cofounder of her multidisciplinary oncology practice, New Mexico Oncology Hematology Consultants Ltd. She also built and manages the New Mexico Cancer Center, which provides comprehensive outpatient medical and radiation oncology care and imaging at several underserved rural areas across New Mexico including sites in Albuquerque, Gallup, Ruidoso, Silver City, and Las Cruces.
In 2012, Dr. McAneny was awarded a $19.8 million grant from the Centers for Medicare & Medicaid Innovation to test how oncology private practices can provide cancer patients with better care at a lower cost, which has positively affected oncology care practices in six states.
Dr. McAneny's second term on the Board will last 4 years.
The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.
